Columnist Jolie Lizana is not just happy to take a day of rest for National Relaxation Day; she contends that such rest is ...

Yutrepia, prescribed to over 900 PAH or PH-ILD patients since its May U.S. approval, increased walking distances by over 100 ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Immune cell metabolism changes may underlie PAH inflammation, which could inform targets for new PAH treatment strategies.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Pulmonary hypertension (PH) is a rare, serious disease characterized by high blood pressure and damaged pulmonary arteries. These vessels, which are responsible for carrying the blood from the right ...

Mutations in certain genes can cause or increase the likelihood of someone developing PAH. This is known as familial or heritable PAH.

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Read about the FDA's approval of Medtronic’s Implantable System for Remodulin (ISR) to deliver the medicine to pulmonary arterial hypertension patients.

The FDA approved under-the-skin injection therapy sotatercept, now Winrevair, for adults in the U.S. with pulmonary arterial hypertension.